An open-label, phase II study of Overex Mab-B43.13 [oregovomab] as an adjuvant treatment to platinum-based front-line chemotherapy of advanced epithelial carcinoma of ovarian, tubal, or peritoneal origin

Trial Profile

An open-label, phase II study of Overex Mab-B43.13 [oregovomab] as an adjuvant treatment to platinum-based front-line chemotherapy of advanced epithelial carcinoma of ovarian, tubal, or peritoneal origin

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2009

At a glance

  • Drugs Carboplatin; Oregovomab; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2009 Status changed from discontinued to completed.
    • 22 Jan 2009 Results were reported in J Immunother in Jan 2009.
    • 21 Jan 2009 Primary endpoint 'Immunological response' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top